given intravenously on the first day and triamcinolone acetonide (10 mg; Westwood Pharmaceuticals, Buffalo, NY) given subcutanously each day throughout the duration of the experiments. With this immunosuppressive regimen, the rabbits have reduced total white blood cell counts through day 7, with a nadir on day 4 [4, 5, 10]. At 24 h after immunosuppression, groups of 8-10 rabbits were challenged intravenously with a lethal inoculum of 106 A. fumigatus conidia or a sublethal challenge of 105 conidia. Antifungal therapy was initiated 24 h after challenge or 48 h before challenge in the prophylaxis studies, as described below. The duration of therapy in surviving rabbits was 5-6 days. Each group contained 1 untreated control rabbit. Blood was obtained daily for determining total white blood cell counts
alone and fluconazole alone improved survival, lowered the tissue burden of infection, and reduced the level of Aspergillus antigenemia in our immunosuppressed rabbit model of infection [4, 8, 9] ; also, prophylaxis with fluconazole before challenge reduced dissemination of infection [10] . However, oral fluconazole did not sterilize infected tissues [5] . Therefore, the present study was designed to evaluate the efficacy of combination antifungal therapy, primarily fluconazole plus amphotericin B, in our immunosuppressed leukopenic rabbit model of invasive aspergillosis, with particular attention to the possibility of antagonism. The efficacy of amphotericin B against Aspergillus fumigatus following fluconazole prophylaxis was also assessed. In addition, the effectiveness of flucytosine combined with either amphotericin B or fluconazole was evaluated.
Methods
The methods used have been described in detail previously [4, 5, [8] [9] [10] [11] [12] . Briefly, in our experimental model, New Zealand White rabbits were immunosuppressed with a single dose of cyclophosphamide (200 mg; Bristol-Myers Squibb, Evansville, IN) given intravenously on the first day and triamcinolone acetonide (10 mg; Westwood Pharmaceuticals, Buffalo, NY) given subcutanously each day throughout the duration of the experiments. With this immunosuppressive regimen, the rabbits have reduced total white blood cell counts through day 7, with a nadir on day 4 [4, 5, 10] . At 24 h after immunosuppression, groups of 8-10 rabbits were challenged intravenously with a lethal inoculum of 106 A. fumigatus conidia or a sublethal challenge of 105 conidia. Antifungal therapy was initiated 24 h after challenge or 48 h before challenge in the prophylaxis studies, as described below. The duration of therapy in surviving rabbits was 5-6 days. Each group contained 1 untreated control rabbit. Blood was obtained daily for determining total white blood cell counts and serum aspergillus antigen levels by our competitive ELISA as described previously [5, [8] [9] [10] [11] [12] .
A modification of the semiquantitative culture technique of Graybill and Kaster [ 13] was used to evaluate and compare the aspergillus tissue burden. Samples of liver, kidney, lung, and brain were manually chopped, weighed, diluted 1:10 (wt/vol) with sterile saline, and homogenized for 25 s with an electric tissue homogenizer (Tri-R Instruments, Rockville Center, NY). Then 1.0-and 0.1-mL volumes of each organ homogenate were plated in duplicate on Sabouraud dextrose and blood agar. The plates were incubated for 24-36 h at 370C, and colonies were counted as described previously [9] . Also, liver, spleen, kidney, lungs, and brain were examined histologically at the time of autopsy or sacrifice (48-72 h after completion of therapy for the treated rabbits) as described previously [ Therapy in rabbits challenged with a lethal inoculum. Immunosuppressed rabbits were challenged with a lethal inoculum of 106 A.fumigatus conidia, divided into groups, and treated with amphotericin B (fungizone; E. R. Squibb 8l Sons, Princeton, NJ), fluconazole (Pfizer, Groton, CT), or a combination of amphotericin B plus fluconazole. Amphotericin B was diluted with 57c dextrose in sterile water at a ratio of 1 mg of drug to 10 mL of diluent and was given intravenously over 30-60 min through a lateral ear vein at 1.5 or 0.5 mg/kg/day for 5 days. Fluconazole was dissolved at 4 mg/mL in sterile water and was administered orally via a gastric gavage tube (American Pharmaseal, Valencia, CA) at 60 or 120 mg/kg/day for 6 days. Another group of rabbits was treated with the combination of low-dose amphotericin B (0.5 mg/kg/day) for 5 days and low-dose fluconazole (60 mg/kg/day) for 6 days. Antifungal therapy was initiated 24 h after challenge in all treatment studies.
In other experiments, groups of rabbits received fluconazole prophylactically before intravenous challenge with a lethal (106 conidia) inoculum. Fluconazole at 60 mg/kg/day was begun 48 h before challenge and was continued daily for 9 days as singledrug therapy or, in some experiments, as combination therapy with amphotericin B at 0.5 mg/kg/day begun 24 h after challenge and given for 5 days.
Therapy in rabbits challenged with a sublethal inoculum. Immunosuppressed rabbits were challenged with a sublethal inoculum of 105 A.fumigatus conidia, subdivided into groups, and treated with amphotericin B alone at 0.25 or 0.5 mg/kg/day for 5 days, fluconazole alone at 60 or 120 mg/kg/day for 6 days, or flucytosine alone at 100 mg/kg/day for 6 days. Flucytosine (Roche, Nutley, NJ) was dissolved in sterile water at a concentration of 10 mg of flucytosine/mL of water and administered orally via a gastric gavage tube. Other groups of rabbits were treated with flucytosine at 100 mg/kg/day for 6 days in combination with either amphotericin B at 0.5 mg/kg/day for 5 days or fluconazole at 120 mg/kg/day for 6 days. Antifungal therapy was initiated 24 h after challenge.
Sublethally challenged rabbits received prophylactic fluconazole at 60 or 120 mg/kg/day initiated 48 h before challenge. Prophylactic fluconazole at 60 mg/kg/day was also given in combination with treatment regimens, begun 24 h after challenge, of 0.25 and 0.5 mg/kg/day of amphotericin B.
Statistical analysis. The two-tailed Wilcoxon rank sum test and x2 analysis were used when appropriate. Statistical significance was defined as P < .05. Recovery of neutropenia appears to be of signal importance in determining prognosis [6] . Therefore, agents with improved efficacy and decreased toxicity are needed to improve the management of aspergillus infections in these patients. Also, antifungal prophylaxis or early empiric antifungal therapy may reduce the morbidity and mortality associated with invasive aspergillosis in high-risk patients [14] [15] [16] [17] . Newer azoles, used alone or in combination with other antifungal agents, may offer several advantages in the treatment of invasive fungal infection. Some of these newer azoles (e.g., fluconazole, itraconazole, and saperconazole) demonstrate several of these advantageous characteristics, including broad-spectrum antifungal activity, excellent absorption after oral administration, and minimal acute toxicity [12] . Fluconazole also has solubility characteristics that permit intravenous administration, extensive central nervous system penetration, and a prolonged half-life in humans [10, 18, 19] . In earlier studies, fluconazole was shown to have significantly more activity against A. fumigatus and Aspergillus flavus than ketoconazole in a murine model [20] . This protective effect of fluconazole against aspergillosis, however, was not confirmed in other studies with a murine model but these results may be due to the relatively rapid clearance of fluconazole in mice [19] .
Results
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Combination therapy with an azole plus amphotericin B or the use of an azole prophylactically followed by amphotericin B therapeutically for invasive aspergillosis may improve the management of patients at risk for this infection [6] . However, the oral imidazole ketoconazole, which has limited in vitro activity against Aspergillus organisms, is not useful for treating patients with invasive aspergillosis and has been shown to be antagonistic to amphotericin B in an experimental model of disseminated aspergillosis [7] . These data have caused some concern about combining an azole with amphotericin B in the treatment of fungal infections. Therefore, the present study was designed to evaluate the efficacy of combination antifungal therapy in our experimental model of invasive aspergillosis, with particular attention to the possibility of antagonism.
In earlier studies in our immunocompromised rabbit model of invasive aspergillosis, amphotericin B alone and fluconazole alone significantly reduced mortality as well as the level of aspergillus antigen in the serum, which correlated with the reduced tissue burden of A. fumigatus compared with untreated control animals [5, 9, 10]. Oral fluconazole reduced the tissue burden of Aspergillus organisms by 10-to 100-fold, but only amphotericin B at 1.5 mg/kg/day sterilized tissues [9, 10] . In the present studies, combination therapy and prophylaxis followed by combination therapy were evaluated in our lethal and sublethal model of invasive aspergillosis in an attempt to determine the efficacy of treatment and prophylaxis in both severe infection and moderate disease.
This rabbit model of invasive aspergillosis provides a rigorous test of efficacy when animals receive a lethal challenge of A. fumigatus. Mortality in untreated animals approaches 100(l). In the present study, survival was significantly prolonged with fluconazole or amphotericin B at all doses studied and with combination therapy, even when lower doses of fluconazole and amphotericin B were used. Antagonism was not observed when amphotericin B and fluconazole were used in combination in these doses as judged by mortality, tissue burden of aspergillus organisms, and serum levels of aspergillus antigen. We also observed a lower mortality in animals given fluconazole alone as prophylaxis compared with the drug as therapy, though these differences were not statistically significant. Also, antagonism was not observed when fluconazole was given prophylactically followed by amphotericin B when evaluated by these same criteria. However, high-dose amphotericin B was the most effective therapy observed in this model, which suggests that higher dosages of amphotericin B may be beneficial in the treatment of invasive aspergillosis.
Similar results were observed in the present studies when animals were given a sublethal challenge. Only rabbits treated with flucytosine had a mortality rate comparable to that of untreated animals. In contrast, lower mortality rates were observed in all other treatment groups, including animals receiving fluconazole alone as treatment or prophylaxis, amphotericin B alone at low doses, or combination therapy with fluconazole plus amphotericin B, fluconazole plus flucytosine, or amphotericin B plus flucytosine. Again, no evidence of antagonism was observed in animals given a combination of two antifungal agents, whether the combination included fluconazole and amphotericin B, flucytosine and amphotericin B, or fluconazole and flucytosine. However, higher-dose amphotericin B was the most effective treatment in animals receiving a sublethal challenge of aspergillus organisms.
Combination antifungal therapy has also been studied in a neutropenic rabbit model of candidiasis, and amphotericin B combined with flucytosine was observed to be the most effective therapy [21] . In these studies, amphotericin B combined with ketoconazole was also superior to amphotericin B alone against infection in the kidney but was not as effective as amphotericin B combined with flucytosine. Importantly, no antagonism was observed between amphotericin B and ketoconazole in that model of candidal infection [21] . Also, recent studies have evaluated the postantifungal effect of flucytosine and fluconazole separately and in combination on Candida albicans in vitro [22] . A synergistic interaction of the two drugs at concentrations well below their individual MICs was observed, and the combination of these two antifungal agents induced a postantifungal effect that persisted 2V2 h longer than those observed with each antifungal agent separately [22] .
Few clinical studies have evaluated the efficacy of combination antifungal therapy or prophylaxis for invasive aspergillosis, and these studies were noncomparative [15, 23] . Nevertheless, the use of amphotericin B combined with flucytosine resulted in survival of 13 of 14 patients with invasive aspergillosis when this therapy was begun very early after the development of symptoms [24] . However, granulocytopenia resolved in all 13 patients who survived the infection. Similarly, the use of high-dose amphotericin B plus flucytosine has been evaluated as prophylaxis in patients who have had a previous episode of invasive aspergillosis and who have required another course of chemotherapy [15] . Antifungal therapy was started 48 h before chemotherapy and continued until resolution of granulocytopenia, and no patient died from invasive aspergillosis [ 15] . In this context, the present studies demonstrated significant improvement in the lung and liver of rabbits given a sublethal challenge of aspergillus organisms and treated with amphotericin B plus flucytosine compared with amphotericin B alone. Antagonism between flucytosine and amphotericin B was not observed. Similarly, antagonism was not observed between fluconazole and amphotericin B or fluconazole and flucytosine in this rabbit model of invasive aspergillosis. Thus, the antagonism reported previously between ketoconazole and amphotericin B [7] does not appear to be present when ketoconazole is replaced by fluconazole in that combination.
